Don't under estimate the immense experience and respect Prof....

Don't under estimate the immense experience and respect Prof. Shoulson brings to the team.

Also, most telling for me was:

Prana Biotechnology CEO and Executive Chairman Geoffrey Kempler said: “Professor Shoulson’s clinical and regulatory experience will be pivotal as Prana prepares to meet with regulators later this year to chart the next steps in PBT2’s development as a treatment for Huntington disease.”

"prepares to meet later this year..." Very interesting!!

What do others make of that one line? By my reckoning, this means we can expect 2 major HD announcements this year:

1. partner or funding to progress to large PIII study
2. FDA go ahead of PIII trial design ("later in the year")

In that sense, we could still have a material announcement (re item 1 above) anytime soon. Can take 3 -6 months to design the trial and I'm guessing that design will be influenced by the extent of funding.